Experimental Pancreatic Cancer Vaccine Triggers Immune Response in Nearly All Treated Patients
A Mayo Clinic-led trial found the camupepimut vaccine sparked anti-KRAS immune activity in 98.9% of evaluable patients, Lenta News reports.
Nov 1, 2026 · 3 min read
128 views